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In Brief
Li et al. developed a recombinase-
enhanced bimolecular luciferase comple-
mentation platform, termed ReBiL, to
evaluate low-affinity protein-protein inter-
actions (PPIs) that are not detectable by
other methods and to analyze PPI antag-
onists in living cells. ReBiL showed that
small-molecule p53-Mdm2 antagonists
disrupt their intended targets effectively
in cells, whereas stapled peptides did
not. Stapled peptides unexpectedly
induced cell membrane disruption result-
ing in p53-independent death associated
with cytoplasmic leakage. ReBiL is also
valuable for high-throughput screening
and for deciphering signaling mecha-
nisms mediated by protein interactions.
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Protein-protein interactions (PPIs) play central roles
in orchestrating biological processes. While some
PPIs are stable, many important ones are transient
and hard to detect with conventional approaches.
We developed ReBiL, a recombinase enhanced
bimolecular luciferase complementation platform,
to enable detection of weak PPIs in living cells.
ReBiL readily identified challenging transient in-
teractions between an E3 ubiquitin ligase and an E2
ubiquitin-conjugating enzyme. ReBiL’s ability to
rapidly interrogate PPIs in diverse conditions re-
vealed that some stapled a-helical peptides, a
class of PPI antagonists, induce target-independent
cytosolic leakage and cytotoxicity that is antago-
nized by serum. These results explain the require-
ment for serum-free conditions to detect stapled
peptide activity, and define a required parameter
to evaluate for peptide antagonist approaches.
ReBiL’s ability to expedite PPI analysis, assess
target specificity and cell permeability, and reveal
off-target effects of PPI modifiers should facilitate
the development of effective, cell-permeable PPI
therapeutics and the elaboration of diverse biological
mechanisms.INTRODUCTION
Most cellular functions are conducted by interactions between
multiple proteins comprising either static or dynamic macromo-
lecular machines. Dynamic protein-protein interactions (PPIs)
are often composed of weak and transient interactions that
render their discovery and analysis in physiologically relevant
environments difficult. The human protein ‘‘interactome’’ may
involve 130,000–650,000 PPIs (Stumpf et al., 2008; Venkate-
san et al., 2009). Even if only a small fraction of these PPIs cause1946 Cell Reports 9, 1946–1958, December 11, 2014 ª2014 The Autdisease through aberrant interactions (Ivanov et al., 2013), the
availability of rapid PPI antagonist screens would open up vast
new opportunities for developing therapeutic agents. Although
fluorescent-image-based assays such as the proximity ligation
in situ assay (P-LISA) (So¨derberg et al., 2006; Bernal et al.,
2010) and two- or three-hybrid assays have been used to eval-
uate PPI antagonists in cells (Brown et al., 2013; Herce et al.,
2013), they do not enable simultaneous evaluation of on-target
validation and facile, high-throughput analysis of target disrup-
tion in living cells. Clearly, methods that would enable real-time
detection of PPIs and direct measurement of their intracellular
disruption by antagonists are needed. To address this need,
we integrated Cre-recombinase mediated cassette exchange
(RMCE) (Wong et al., 2005) and bimolecular luciferase comple-
mentation (BiLC) (Luker et al., 2004) in an inducible gene-expres-
sion format to create a platform system for detecting and
analyzing PPIs. We refer to this approach as recombinase-
enhanced BiLC and use the acronym ReBiL for concision as
well as to precisely and simply describe the integration of its
key components.
We applied ReBiL to two outstanding problems to assess
the potential breadth of biological problems it could be used
to study. First, we evaluated its ability to detect weak,
transient PPIs in living cells, as exemplified by the interaction
of the E2 ubiquitin-conjugating enzyme UBE2T and FANCL,
the E3 ubiquitin ligase to which it binds. FANCL is a critical
component of the Fanconi anemia DNA repair pathway.
Mutations in this pathway cause hematologic abnormalities
and create a predisposition to develop cancer (Moldovan and
D’Andrea, 2009). E2-E3 interactions are usually transient
and typically occur in the low micromolar range (Deshaies
and Joazeiro, 2009; Ye and Rape, 2009), which makes their in-
teraction difficult to detect. Although the interaction between
UBE2T and FANCL E3 ligase was shown in a yeast two-hybrid
screen (Machida et al., 2006), it has eluded detection in living
mammalian cells. The UBE2T-FANCL dissociation constant
was measured as 0.454 mM by isothermal titration calorimetry,
but this required analysis at 8C (Hodson et al., 2011). Fur-
thermore, it was shown that cocrystallization of UBE2T and
FANCL required their fusion (Hodson et al., 2014), consistenthors
with the fact that they associate with low affinity. Therefore,
using ReBiL to assess the association of UBE2T and FANCL
provides a stringent test of its ability to detect such challenging
interactions.
The second system to which we applied ReBiL involves the
p53 tumor suppressor. Defects in the p53 pathway occur in
as many as 22 million cancer patients, and 50% of these
defects are due to inactivating mutations in p53 itself (Brown
et al., 2009). Many of the remaining tumors contain alterations
that lead to overexpression of either of two oncogenes
(Mdm2 and Mdm4) that bind to wild-type p53 and inactivate
it by serving as an E3 ubiquitin ligase (Mdm2) and/or a tran-
scriptional repressor (Mdm2 and Mdm4). Therefore, drugs
that could interfere with p53-Mdm2 and p53-Mdm4 interactions
could restore p53 function and significantly benefit patients
whose cancers express wild-type p53 (Brown et al., 2009;
Wade et al., 2013).
Unlike classic enzyme-ligand-binding pockets that can be
effectively targeted by small molecules, the surfaces on which
protein domains interact are typically large, flat, and featureless
(Wells and McClendon, 2007). Nevertheless, several PPI antag-
onists that disrupt p53-Mdm2, p53-Mdm4, or both have been
reported (Brown et al., 2009; Wade et al., 2013). Recently,
stapled a-helical (SAH) peptides have been designed and sug-
gested as the model for superior PPI antagonists because of
their larger interaction interfaces, better structural stability, pro-
tease resistance, and cell permeability (Verdine and Hilinski,
2012). Conventionally, the effectiveness of a PPI antagonist
has been evaluated by means of in vitro biochemical and bio-
physical assays that quantify the ability of the antagonist to
displace one of the interacting protein fragments. However,
such assays do not reveal whether molecules that work effec-
tively in in vitro systems can cross the cell membrane to effect
target disruption in a native intracellular environment. While
fluorescence-activated cell sorting (FACS) analyses have been
used to indicate whether fluorophore-tagged PPI antagonists
can enter cells, they do not reveal the subcellular localization
(e.g., endosome versus cytoplasm) of the antagonists or
whether they reach their targets at concentrations sufficient to
disrupt the PPIs and elicit biological effects. Furthermore,
assays of biologic activities such as cell death can be
misleading and do not provide direct evidence of the intracel-
lular efficacy of a PPI antagonist. For example, since p53 can
be activated by diverse cellular insults and many different
mechanisms (Beckerman and Prives, 2010), the ability of a
putative PPI antagonist to activate p53 target genes or p53-
dependent biological processes does not prove that these
effects were directly mediated by disruption of p53-Mdm2
and/or p53-Mdm4 complexes.
Here, we report that ReBiL can detect transient and weak
PPIs, such as those between UBE2T and FANCL. Additionally,
ReBiL enabled us to elucidate on- and off-target activities of
SAH peptides, as well as a mechanism by which serum antago-
nizes SAH-peptide-induced membrane damage. Because of its
sensitivity, specificity, and versatility, the ReBiL platform should
find broad applications for elucidating biological mechanisms
and screening for small-molecule- and peptide-based PPI
antagonists.Cell ReRESULTS
Development of the ReBiL Platform System
We use the firefly BiLC (Luker et al., 2004), a type of protein-frag-
ment complementation assay (PCA) (Michnick et al., 2007), to
study PPIs and their antagonists because it has two unique
advantages. First, the lack of background luminescence in
mammalian cells creates an opportunity for high sensitivity.
Second, while split fluorescent proteins associate irreversibly,
firefly split luciferase fragments exhibit little if any interaction
by themselves, enabling rapid dissociation of complementing
pairs (Yang et al., 2009; Ilagan et al., 2011; Macdonald-Ober-
mann et al., 2012). These features make BiLC ideal for
analyzing PPI stability and ascertaining the effectiveness of PPI
antagonists.
Firefly luciferase PCA relies on the reconstitution of luciferase
enzymatic activity from two split fragments and the interaction of
the proteins to which they are genetically fused (Luker et al.,
2004; Figure 1A). Typical BiLC experiments utilize transient
transfection of two plasmids encoding each split luciferase
fusion partner (Luker et al., 2004; Paulmurugan and Gambhir,
2007; Cassonnet et al., 2011; Gilad et al., 2014). Consequently,
the sensitivity, accuracy, and reproducibility of these experi-
ments are profoundly influenced by the percentage of cells
that have been transfected and the copy numbers of each ex-
pressed plasmid. Alternatively, one can also perform BiLC after
selecting for stable cell clones that carry both split luciferase
fusions, such as in studies of EGF receptors and the Notch
pathway (Yang et al., 2009; Ilagan et al., 2011; Macdonald-
Obermann et al., 2012). However, screening and identifying
stable clones with appropriate expression levels is often time-
consuming and labor intensive, and does not enable the gener-
ation of isogenic lines to compare the activities of mutant and
wild-type alleles.
We overcame these drawbacks by generating the ReBiL plat-
form (see Table S1 for feature descriptions). Cre recombinase is
used to insert a ReBiL targeting cassette encoding both split
luciferase fusion partners into a predetermined floxed acceptor
locus integrated at a single chromosomal site in host cells
(Wong et al., 2005; Green et al., 2013; Figure S1). High RMCE
integration efficiency and faithful transgene expression at a pre-
determined genomic locus (Wong et al., 2005) circumvent the
tedious and costly processes involved in screening reporter
clones generated by random integration or viral infection. This
greatly accelerates the production of stable reporter cell lines
and enables the routine generation of nine to 12 stable ReBiL
cell lines in 4–6 weeks with minimum effort, and could likely be
scaled up with the use of robotics.
The ReBiL platform provides two other significant experi-
mental and analytical advantages over other stable clones. First,
it facilitates structure, function, and interaction analyses
because it enables BiLC fusions encoding wild-type and mutant
proteins to be integrated into and expressed homogeneously
from the same chromosomal locus (Figure S1). Second, single-
copy integration and doxycycline-tunable regulation of trans-
genes (Figure 1B) generate rheostatic and uniform expression
(Rossi et al., 2000; Wong et al., 2005) that can be tuned to
physiologically relevant levels. Together, these implementationsports 9, 1946–1958, December 11, 2014 ª2014 The Authors 1947
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Figure 1. Description of the ReBiL Platform
System and Expected Results Generated
by PPIs and Antagonists
(A) Cartoon depicting the BiLC strategy to detect
PPIs and their disruption by antagonists.
(B) Expression of a ReBiL cassette was controlled
by both TetR-KRAB in the absence of doxycycline
(top panel) and rtTA2S-M2 in the presence of
doxycycline (bottom panel). The numbers in open
circles indicate each key component in the ReBiL
platform system (see Table S1).
See also Figure S1.significantly enhance the reproducibility and signal-to-noise ratio
of the firefly luciferase PCA.
ReBiL Enhances Detection of Weak PPIs
We compared BiLC signals generated by transient transfection,
ReBiL, and random integration approaches. We used the iden-
tical inducible reporter constructs encoding either UBE2T and
FANCL or UBE2T and the FANCL_C307A mutation (Figure S2A;
Table S2). FANCL-C307A is a RING domain mutation that pre-
vents interaction with UBE2T (Machida et al., 2006) and serves
as a negative control. The luminescent signals generated in
transiently transfected cells and random integrants were barely
statistically different between the specific interaction pair
(UBE2T-FANCL) and the mutant pair (UBE2T-FANCL_C307A)
(Figure 2A). In stark contrast, the UBE2T-FANCL ReBiL cells
generated 5-fold higher luminescent signals than the UBE2T-
FANCL_C307A mutant ReBiL cells (Figure 2A, middle panel) at
35C. The expression levels of FANCL_C307A were higher
than those of its wild-type counterpart, which corresponded to
increased levels of UBE2T, regardless of whether transfection
or ReBiL was used (Figure 2B). Importantly, the level of intro-
duced UBE2T was always lower than that of the endogenously
produced protein (Figure 2C), but due to a lack of validated
FANCL antibody, we could not evaluate its endogenous level.1948 Cell Reports 9, 1946–1958, December 11, 2014 ª2014 The AuthorsWe also note that UBE2T and FANCL
expression did not affect cell viability (Fig-
ure 2D). Thus, the absence of BiLC signal
in the UBE2T and FANCL_C307A cells
must result from their inability to interact
rather than a difference in protein level
and cell viability. The very low BiLC sig-
nals from the random integrant pool (Fig-
ure 2A, right) correlates with the low
expression levels of the BiLC pairs (Fig-
ure 2B), consistent with a recent report
showing that PPIs depend strongly on
abundance (Levy et al., 2014). It is espe-
cially significant, therefore, that ReBiL
manifests a robust signal-to-noise ratio
between these weakly interacting pro-
teins even when at least one of them is ex-
pressed at lower than endogenous levels.
Intriguingly, at lower temperature (30C),
both ReBiL and random integrated cellsgenerated higher total BiLC signals and signal-to-noise ratios
(10-fold inReBiLcells;FigureS2B)withoutmuchdifference in the
levels of expressed split luciferase fusions (Figure S2C) compared
with 35C (Figure 2B). Similarly, the expressed split-luciferase-
UBE2T fusion was less abundant than endogenous UBE2T endo-
genous UBE2T at 30C (Figure S2D), and no growth differences
between wild-type and mutant cells were observed (data not
shown). This temperature dependency is consistent with the low
affinity of these interacting proteins and may indicate that at
30C,UBE2T-FANCLhas a lower dissociation rate (higher affinity).
Importantly, at both temperatures, the ReBiL platform exhibited
a significantly enhanced ability to detect weak and transient PPIs.
Analysis of Protein Interactions in the p53 Pathway
using ReBiL
Several small-molecule- and peptide-based compounds have
been reported to interfere with p53-Mdm2 and p53-Mdm4 inter-
actions in biophysical assays and to activate p53 in living cells
(Brown et al., 2009; Wade et al., 2013). However, recent data
have raised questions about the ability of some SAH peptides
to interfere with p53-Mdm2 and p53-Mdm4 interactions in cells
(Brown et al., 2013). Therefore, we used the ReBiL system to
evaluate small-molecule-, SAH peptide-, and cyclotide-based
p53-Mdm2 and p53-Mdm4 PPI antagonists.
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Figure 2. Detection of Low-Affinity UBE2T and FANCL Interaction with ReBiL
(A) ReBiL detected UBE2T and FANCL interaction with a significantly higher signal-to-noise ratio. Luminescent signals in the transient transfection, ReBiL, and
randomly integrated reporter cells were compared at 35C. Data shown are mean ± SEM from three independent experiments.
(B) Western blot analysis of BiLC fusion proteins. nLuc-HA-UBE2T, cLuc-FLAG-FANCL_WT, and cLuc-FLAG-FANCL_C307Awere detected by anti-HA and anti-
FLAG, respectively. Actin served as a loading control.
(C) Western blot analysis of the levels of nLuc-UBE2T and endogenous UBE2T by anti-UBE2T (Cell Signaling). Actin served as a loading control.
(D) CellTiter-Glo assay indicated there was no growth difference between FANCL_WT and FNACL_C307A cells. Data shown are mean ± SEM from three
independent experiments.
See also Figure S2.We used two strategies to avert cytotoxicity or cell-cycle
arrest that could be generated by wild-type p53 activation. First,
we used p53 null Saos-2 cells as the host for the ReBiL reporter
cell line. Second, we combined two p53 mutations, the R273H
(Joerger and Fersht, 2008) and C312 truncation (Vassilev et al.,
2004), to build a transcriptionally inactive split luciferase p53
fusion that could interact with Mdm2 and Mdm4 (Figure S3A;
Table S2).
We evaluated the specificity of ReBiL for studying p53-Mdm2
interaction with their antagonist Nutlin-3a, which is known to
disrupt p53-Mdm2, but not p53-Mdm4, interactions (Vassilev
et al., 2004; Patton et al., 2006; Wade et al., 2008). As expected,
Nutlin-3a reduced the p53-Mdm2, but not the p53-Mdm4, BiLC
signal (Figure 3A). Signal reduction did not result from Nutlin-3a-
induced effects on protein levels (Figure 3B) and cell viability
(data not shown). These data demonstrate the specificity of the
ReBiL system for discriminating between a small molecule’s
ability to prevent interaction between p53 and the two very
similar binding sites in Mdm2 and Mdm4 in vivo.
Whether small molecules like Nutlin-3a disrupt preformed
p53-Mdm2 complexes in living cells has remained an openCell Requestion. We used ReBiL to investigate this by first inducing
expression of the p53- and Mdm2-split luciferase fusion pairs
to generate a functional BiLC complex, and then removing doxy-
cycline to prevent their further transcription. Subsequent incuba-
tion of the ‘‘preloaded’’ cells with Nutlin-3a enabled us to analyze
the decay of the p53-Mdm2 BiLC complex in living cells. The
p53-Mdm2 complexes decayed over time, and this was acceler-
ated significantly and dose dependently by Nutlin-3a (Figure 3C,
left panel). Western blotting analysis indicated that Nutlin-3a did
not promote degradation of BiLC fusion proteins (Figure 3D,
compare lanes 2 and 3). Since doxycycline withdrawal stops
p53- and Mdm2-split luciferase fusion transcription, but not
translation, we added cycloheximide to prevent translation and
then determined dissociation with and without Nutlin-3a. We
determined luminescence every minute during a 40 min time
period after inhibiting transcription and translation. Similar to
what we observed in longer-duration experiments (Figure 3C),
Nutlin-3a dose-dependently reduced p53-Mdm2 BiLC signals
within 20 min, cycloheximide did not appreciably affect the ki-
netics (Figure S3B), and p53- and Mdm2-BiLC fusion protein
levels remained unchanged during the short time period of theports 9, 1946–1958, December 11, 2014 ª2014 The Authors 1949
A B
C D
Figure 3. Real-Time BiLC Analyses Faithfully Report PPIs and Activity of the p53-Mdm2 Antagonist
(A) Nutlin-3a prevents newly synthesized p53-Mdm2, but not p53-Mdm4, interactions. Saos-2 p53-Mdm2 and p53-Mdm4 ReBiL cells in 384-well plates (8,500
cells per well) were treated with 500 ng/ml doxycycline, 100 mM D-luciferin, and 10 mMNutlin-3a or DMSO at time = 0. Luminescence was read every 30 min for
24 hr at 37C. Data shown are from a representative experiment out of more than three independent experiments.
(B)Western blot analysis of BiLC fusion proteins showed that Nutlin-3a does not affect the expression amounts of nLuc-HA-p53 and cLuc-FLAG-Mdm2 (detected
by anti-HA and anti-FLAG, respectively). Actin served as a loading control.
(C) Preinduced Saos-2 p53-Mdm2 and p53-Mdm4 ReBiL cells were reseeded into a 384-well plate (5,000 cells per well) together with Nutlin-3a and D-luciferin at
time = 0. The p53-Mdm2 and p53-Mdm4 BiLC signals decayed over time in a biphasic fashion. The first steep decline in BiLC signal is likely due to the tem-
perature changes of the ReBiL cells when moving from the bench (24C) to the prewarmed luminometer at 37C. The second slow-decay phase of BiLC results
from doxycycline withdrawal and the consequent reduction in transcription of the BiLC fusion genes. Luminescence was read every 10min for 10 hr at 37C. Data
shown are from a representative experiment out of more than three independent experiments.
(D) Western blot analysis showed that Nutlin-3a did not promote nLuc-HA-p53 and cLuc-FLAG-Mdm2 degradation. Actin was a loading control.
See also Figure S3.analysis (Figure S3C). The p53-Mdm4 complexes were not
affected by Nutlin-3a regardless of cycloheximide addition (Fig-
ure S3D). These data show that small-molecule PPI antagonists
such as Nutlin-3a can selectively and rapidly disrupt preformed
p53-Mdm2 complexes in living cells.
Disruption of p53-Mdm4 complexes has been an important
goal for reactivation of wild-type p53 in cancer therapy (Wade
et al., 2013). We used ReBiL to determine whether a previously
reported small-molecule p53-Mdm4 antagonist, SJ-1725501950 Cell Reports 9, 1946–1958, December 11, 2014 ª2014 The Aut(Reed et al., 2010), disrupts this interaction in cells. No decrease
in p53-Mdm4 BiLC signal was detected (Figure S3E). We then
evaluated a second compound, RO-5963, that has been pro-
posed to disrupt both p53-Mdm2 and p53-Mdm4 interactions
by increasing Mdm2-Mdm4 association (Graves et al., 2012).
Consistent with this model, RO-5963 increased the BiLC signal
in the Mdm2-Mdm4 N-terminal BiLC pair (Figures S3F and
S3G). However, even though the Mdm2 binding affinity of
RO-5963 (17.3 nM) is similar to that of Nutlin-3a (18.7 nM)hors
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Figure 4. Analysis of the Ability of SAH Peptides to Disrupt p53-Mdm2 and p53-Mdm4 Complexes in Living Cells, and Antagonism by Serum
(A–D) Saos-2 p53-Mdm2 and p53-Mdm4 ReBiL cells in 96-well plates (20,000 cells per well) were preinduced by doxycycline (500 ng/ml for 24 hr). At time = 0,
cells were washed with DMEM and treated with new media containing different PPI antagonists with or without 10% FBS. Luminescent signals were read every
5 min for 6 hr in a Tecan-M200 microplate reader at 37C. The ReBiL cells were treated with (A) Nutlin-3a and 10% FBS, (B) ATSP-7041 and 10% FBS, (C)
Nutlin-3a and no FBS, and (D) ATSP-7041 and no FBS. Data shown are from a representative experiment out of more than three independent experiments.
See also Figure S4.(Graves et al., 2012), RO-5963 exhibited a limited ability to
disrupt the p53-Mdm2 complex and no effect on the p53-
Mdm4 complex in living cells (Figure S3H). Intriguingly, although
Nutlin-3a binds to the same Mdm2 N-terminal domain as
RO-5963 (Graves et al., 2012), it did not promote Mdm2 and
Mdm4 N-terminal domain interactions (Figure S3G, right panel).
These data demonstrate the exquisite specificity of the ReBiL
strategy for revealing both the agonist and antagonist activities
of putative PPI modifiers in vivo.
SAH Peptides Do Not Efficiently Disrupt p53-Mdm2 and
p53-Mdm4 Interactions in Living Cells
We next determined whether the ability of SAH peptide-based
antagonists that have been shown to disrupt p53-Mdm2 and
p53-Mdm4 interactions in vitro also do so in living cells. We
analyzed SAHp53-8 (Bernal et al., 2007, 2010), sMTide-02
(Brown et al., 2013), and ATSP-7041 (Chang et al., 2013). The
larger binding surfaces of these peptidic drugs confer far higher
binding affinities than Nutlin-3a, as exemplified by ATSP-7041
with a Ki = 0.9 nM for Mdm2 compared with Ki = 52 nM for
Nutlin-3a (determined by Chang et al., 2013). Surprisingly,
despite this much higher binding affinity, SAH peptides are typi-
cally used at higher concentrations (20–100 mM) to elicit cellular
activities (Bernal et al., 2010; Gembarska et al., 2012; Chang
et al., 2013; Brown et al., 2013). Indeed, in spite of its 57-fold
higher binding affinity, ATSP-7041 (10 mM) reached full p53-
Mdm2 inhibition much more slowly (4 hr) than Nutlin-3a
(20 min; compare Figures 4A and 4B). ATSP-7041 exhibited
only marginal activity against p53-Mdm4 complexes (Figure 4B,
right). Surprisingly, SAHp53-8 and sMTide-02 exhibited no
detectable ability to disrupt p53-Mdm2 or p53-Mdm4 com-
plexes in living cells (Figures S4B and S4C). Paradoxically,Cell ResMTide-02 actually increased BiLC signals in a dose-dependent
fashion for both p53-Mdm2 and p53-Mdm4 complexes by an
unclear mechanism (Figure S4C).
These results indicate that higher binding affinity in vitro does
not necessarily correlate with higher intracellular PPI disruption
activity, suggesting that theremight be a barrier to effective entry
of the SAH peptides into the cells. The increased activity of
ATSP-7041 in 0%serum (Chang et al., 2013; Figure 4D) indicates
that the serum itself might limit the intracellular access of the
SAH peptides, which would be consistent with prior studies in
which the cellular activity of SAH peptides was typically
measured in serum-free medium (Bernal et al., 2010; Edwards
et al., 2013; see Figure S5). Since the mechanism for serum-
mediated inhibition of SAH peptides has remained elusive, we
investigated this more fully, as described below.
Dual Mdm2 and Mdm4 Antagonist SAH Peptides Exhibit
p53-Independent Cytotoxicity
Because the ReBiL system enables real-time analysis of the ki-
netics of target disruption in cells, we were able to determine
when target disruption occurred and then correlate that with
other parameters, such as cell viability. We noticed that wild-
type SAH peptides rapidly (6 hr) and dose dependently
reduced the viability of p53 null Saos-2 ReBiL cells (Figure 5).
This cytotoxicity is p53 independent, since the Saos-2 ReBiL
cells are p53 null and they were engineered to encode a tran-
scriptionally inactive split-luciferase p53 fusion protein. This
also occurred in Saos-2 cells expressing BRCA1-BARD1 BiLC
fusion proteins (Brzovic et al., 2001; Figure 5C; Table S2). Sur-
prisingly, the negative control mutant peptides exhibited neither
PPI disruption (Figure S4) nor significantly reduced cell viability,
even in serum-free media (Figure 5). Importantly, 10% serumports 9, 1946–1958, December 11, 2014 ª2014 The Authors 1951
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Figure 6. The BiLC Lysate Assay Reveals that Serum Does Not Prevent SAH Peptides from Disrupting p53-Mdm2 or p53-Mdm4 Complexes
(A) Cellular lysates obtained from p53-Mdm2 and p53-Mdm4 ReBiL cells were coincubated with the indicated PPI antagonists in the absence of FBS in 384-well
plates at room temperature for 10 min. Steady-Glo was added, and luminescence was detected at 26C.
(B) BiLC lysate assays were performed as in (A) except for the inclusion of 10% FBS. The data shown are from a representative experiment out of more than three
independent experiments and were normalized to the luminescent reading of DMSO (set to 100%).
See also Figures S6 and S7.prevented loss of cell viability induced by wild-type SAH pep-
tides (Figure 5) and also reduced the effectiveness of ATSP-
7041 (Chang et al., 2013; compare Figures 4B and 4D). Similarly,
lower concentrations of ATSP-7041 and sMTide-02 peptides
also reduced Saos-2 viability in 24 hr in a serum-dependent
manner (Figure 5D). These data imply that these p53-activating
SAH peptides can elicit p53-independent cytotoxicity, which is
inhibited by serum. As reported previously (Liu et al., 2010),
high Nutlin-3a concentrations also induce p53-independent
cytotoxicity (Figure 5), likely by off-target effects different from
those of SAH peptides (discussed in Figure 7).
Dual Mdm2 and Mdm4 Antagonist SAH Peptides Exhibit
Strong Target Disruption Activity in Cell Lysates
We consider the following as two reasonable explanations for
serum’s ability to both prevent SAHpeptide-induced cytotoxicity
and reduce the efficacy of PPI disruption: first, serum may bind
SAH peptides in such a way as to prevent them from disruptingFigure 5. Viability Assay of Saos-2 ReBiL Cells Reveals that p53-Act
Absence of Serum
(A–C) Cell viability was measured by CellTiter Glo assay at 6 hr after Saos-2 ReBiL
the indicated SAH peptides without and with 10% FBS. The data shown are from
and were normalized to the luminescent reading of DMSO (set to 100%).
(D) Saos-2 cells were treated with the indicated SAH peptides in 384-well plate
detected by CellTiter Glo assay. The data shown are the mean ± SD from two
DMSO (100%).
See also Figures S5 and S7.
Cell Retheir target complexes; second, serummay prevent SAHpeptide
entry into cells to both reduce their efficacy and limit cytotoxicity.
We gained insights into these possibilities by developing a
cell-free BiLC assay. We reasoned that if SAH peptides effi-
ciently disrupt PPIs in cell lysates, but not in intact cells, then
membrane penetration and access to their intracellular targets
might be limiting. We induced expression of the BiLC complexes
by doxycycline and then prepared cell lysates using an opti-
mized buffer (PPI lysis buffer [PLB]; Figure S6). In contrast to
in vitro binding competition assays that use purified protein frag-
ments to identify PPI antagonists, the BiLC lysate assay contains
all soluble cellular proteins extracted by PLB and therefore
should reveal PPI inhibitor potency in amore physiologically rele-
vant context.
Consistent with the cell-basedBiLC assay, Nutlin-3a efficiently
disrupted p53-Mdm2, but not p53-Mdm4, complexes in the
lysate BiLC assay (Figures 6 and S6E). SJ-172550 (Reed et al.,
2010), RO-5963 (Graves et al., 2012), and pyrrolopyrimidineivating SAH Peptides Possess p53-Independent Cytotoxicity in the
cells (A, p53-Mdm2; B, p53-Mdm4; and C, BRCA1-BARD1) were treated with
a representative experiment out of more than three independent experiments
(2,000 cells per well) without and with 10% FBS for 24 hr. Cell viability was
independent experiments and were normalized to the luminescent reading of
ports 9, 1946–1958, December 11, 2014 ª2014 The Authors 1953
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Figure 7. Stapled Peptides Induce Mem-
brane Leakage by a p53-Independent Mech-
anism that Is Antagonized by Serum
(A) Saos-2 cells were treated with the indicated PPI
antagonists at 25 mM and 10 mM for 6 hr. Accu-
mulation of cytoplasmic LDH in the growthmedium
was used as a metric of cell membrane damage.
LDH was detected by the CytoTox 96 Non-
Radioactive Cytotoxicity Assay Kit (Promega). The
lysed sample represents the maximum LDH
leakage in this experiment and its reading was set
to 100%. DMSO treatment served as the vehicle
control and its value was set to 0%.
(B) Normal human fibroblasts (WS1 cells) were
treated exactly as in (A). Data are shown as mean ±
SEM from two independent experiments.
See also Table S3.compound 3b (Lee et al., 2011) exhibited no activity in the lysate
BiLC assays (Figure S6E), confirming their poor intracellular PPI
disruption activity (Figures S3E and S3H). In contrast, SAHp53-
8, sMTide-02, and ATSP-7041 were potent p53-Mdm2 and
p53-Mdm4 interaction disruptors in the lysate BiLC assays (Fig-
ure 6A), and negative control peptides with mutations in amino
acids (Phe, Trp, and Leu) that are known to mediate p53 interac-
tions withMdm2 andMdm4were inactive (Figure 6A). The lack of
effect of any of these compounds on BRCA1-BARD1 BiLC ex-
cludes the explanation that active SAH peptides are simply lucif-
erase inhibitors (Figure S7). These results demonstrate that
SAHp53-8 and sMTide-02 are indeed potent PPI antagonists
when they can access their targets. This combination of ReBiL
assays in cellular lysates and live cells provides a simple and effi-
cient strategy for quickly assessing the specificity and potency of
putative PPI antagonists and indicates when poor activity may
derive from inefficient intracellular target access.
The inhibitory effect of serum on SAH peptides could result
from direct binding of serum proteins to the peptide (Bird et al.,
2014). We added 10% fetal bovine serum (FBS) to the lysate
BiLC assays to determine directly whether serum reduces the
ability of stapled peptides to disrupt p53-Mdm2 and p53-
Mdm4 interactions. Serum did not reduce the potency of
ATSP-7041, SAHp53-8, or sMTide-02 in cell lysates (Figure 6B).
These results demonstrate that serum components or proteins
do not sequester or modify SAH peptides and affect their ability
to disrupt the target complexes.
Dual Mdm2 and Mdm4 Antagonist SAH Peptides Cause
p53-Independent Cell Membrane Damage
Given the data presented above, we conjectured that serum
might compromise the ability of SAH peptides to enter the cell.
We also wondered whether there might be amechanistic linkage
between the reduced cytotoxicity and reduced PPI disruption by1954 Cell Reports 9, 1946–1958, December 11, 2014 ª2014 The AuthorsSAH peptides in cells exposed to serum-
containing medium. We reasoned that if
SAH peptides compromise membrane
integrity, they should be able to gain ac-
cess to the cytoplasm and their targets,
and, by extension, the serum effect couldbe explained if it antagonized suchmembrane effects. We tested
this possibility by examining the integrity of membranes after
they were exposed to SAH peptides in the presence or absence
of 10% serum. We quantified release of the cytosolic enzyme
lactate dehydrogenase (LDH) into the culture medium as an indi-
cator of the loss of cell membrane integrity. The data clearly
show that ATSP-7041, sMTide-02, and SAHp53-8 all caused
LDH leakage in the absence of serum (Figure 7). In contrast,
10% serum protected the cell membrane from the damage
induced by these SAH peptides (Figure 7). This cell-mem-
brane-damaging activity is p53 independent, since the LDH
assay was performed in p53 null Saos-2 cells (Figure 7A). The
membranes of normal human WS1 fibroblasts were also
damaged by SAH peptides, indicating that this process is not
restricted to cancer cells (Figure 7B). Surprisingly, all three
mutant stapled peptides lacked this cell-membrane-damaging
activity (Figure 7). Importantly, Nutlin-3a did not induce mem-
brane leakage, excluding the possibility that the cytotoxicity
observed when it is used at high concentrations results from
membrane damage (Figure 5).
We also examined the activities of several PMI-based p53-
Mdm2 and p53-Mdm4 antagonists, as these are high-affinity
Mdm2-binding peptides obtained through screening phage
display libraries (Pazgier et al., 2009; Table S3; Supplemental
Experimental Procedures). The lysate BiLC assay showed that
all were highly potent p53-Mdm2 and p53-Mdm4 antagonists
(Figure S6F). Unfortunately, they all lacked intracellular p53-
Mdm2 and p53-Mdm4 disruption activity in 10% serum media
(data not shown). In the absence of serum, all but one
(McoTi-1-PMI; data not shown) damaged cell membranes in a
p53-independent fashion that was exacerbated by inclusion of
TAT-penetrating peptides (Wadia et al., 2004; Figure 7). Taken
together, our studies show that serum does not prevent SAH
peptides from binding to their targets. Instead, serum protects
cell membranes from being damaged by a previously unrecog-
nized membrane-disrupting activity of wild-type SAH peptides.
DISCUSSION
The ReBiL vectors and cell lines described here constitute a plat-
form system that is able to detect weak and transient PPIs, and
elucidate the structure-activity relationships of PPI antagonists
and agonists. It is sensitive, specific, and can be used to analyze
PPIs in both living cells and cell-free systems. For example, we
quickly confirmed that small-molecule Nutlin-3a interferes with
p53-Mdm2, but not p53-Mdm4, interactions. In contrast, other
published antagonists (SJ-172550 and RO-5963) showed little
if any PPI disruption activity in cells. Our observations suggest
that the reported p53-activating effects of these compounds
may result from induction of other cellular stresses (Beckerman
and Prives, 2010), and not completely from p53-Mdm2 or p53-
Mdm4 disruption. Therefore, there can be a lack of concordance
between in vitro biophysical and biochemical assays and in vivo
biological readouts. This highlights the critical importance of
using an assay that directly analyzes target disruption in cells
to deduce the mechanism of action, such as ReBiL.
The ReBiL approach also led to insights concerning the con-
flicting results of studies using SAH peptides (Brown et al.,
2013; Okamoto et al., 2013, 2014). Considerable effort and re-
sources have been expended to develop SAH peptides as PPI
antagonists. Given the difficulty of developing small-molecule
p53-Mdm4 disruptors, SAH peptides were developed as dual
p53-Mdm2 and p53-Mdm4 antagonists, since Mdm2 and
Mdm4 contain similar N-terminal hydrophobic clefts that interact
with p53. Consistent with expectations, SAH peptides that target
this region were shown to have high binding affinities (Bernal
et al., 2010; Chang et al., 2013; Brown et al., 2013) and the ability
to disrupt both p53-Mdm2 and p53-Mdm4 complexes in vitro
(Figure 6). However, there has been much debate about their
cell permeability (Okamoto et al., 2013; Brown et al., 2013) and
their ability to elicit p53-dependent biological responses (Brown
et al., 2013). For example, in contrast to a previous report (Bernal
et al., 2010), a recent study found that the SAHp53-8 lacked
cytotoxicity and failed to activate a p53 reporter in cell-based
analyses (Brown et al., 2013). Our results clearly show that the
stapled peptides SAHp53-8 and sMTid-02 exhibited little to no
intracellular activity in the presence or absence of serum (Figures
S4B, S4C, S4F, and S4G). This likely accounts for the discor-
dance between their nanomolar binding affinities in vitro and
their marginal ability to generate p53-dependent cytotoxic re-
sponses. ATSP-7041 did antagonize p53-Mdm2 association,
but surprisingly had little effect on p53-Mdm4 complexes. How-
ever, high concentrations and long time periods were required
for any effects to occur. We suggest that this relates to the ability
of ATSP to disrupt membranes, which is partly mitigated by
serum, and that its strong affinity forMdm2 enables it to accumu-
late to a sufficient intracellular concentration for target disrup-
tion, though less efficiently and more slowly than Nutlin-3a.
It has been observed that serum decreases the biological
activity of SAH peptides (Edwards et al., 2013; Chang et al.,
2013; Brown et al., 2013). Our in vitro analyses demonstrated
that serum does not prevent SAH peptides from disrupting eitherCell Rep53-Mdm2 or p53-Mdm4 complexes. The live-cell analyses
showed that all wild-type SAH peptides tested possessed the
unexpected ability to elicit p53-independent membrane damage
that correlated with cytotoxicity. Addition of serum prevented
both membrane damage and cytotoxicity. Surprisingly, muta-
tions that replaced an essential phenylalanine with alanine in
the a-helical region of each peptide abrogated membrane per-
meabilization and cytotoxicity. We infer that this derives from
the ability of these mutations to alter the hydrophobicity and
a-helicity of the peptides (Bernal et al., 2007). Previously, the
cytotoxicity of the wild-type SAH peptides was interpreted to
derive from p53-dependent activity, since mutant control pep-
tides did not exert this effect (Bernal et al., 2010; Chang et al.,
2013; Brown et al., 2013). However, our data show that the
lack of effect in these mutant peptides is actually due to their
inability to permeabilize membranes. Our data are consistent
with a recent microscopic study showing that a fluorescent
FAM conjugated mutant (F19A) ATSP peptide exhibited limited
cellular permeability compared with the apparent cellular distri-
bution of the wild-type ATSP peptide (see Figure 3 in Chang
et al., 2013). This agrees with our conclusion that wild-type
SAH peptides access the cytoplasm after first compromising
membrane integrity. Taken together, these data show that the
observed cytotoxicity of the wild-type SAH peptide does not
completely depend on functional p53, and the absence of
activity in the mutant peptide is related more to its biophysical
properties than to its inability to interact with Mdm2 and Mdm4.
We speculate that membrane disturbance may commonly
result from positively charged cell-penetrating peptides (CPPs)
appended to peptides with exposed hydrophobic residues. For
example, the stapled PMI-PenArg (a lysine-to-arginine derivative
of the CPP penetratin) elicited cell death within 3 hr in cells
growing in serum-free media (data not shown). Similarly, the
cationic cell-penetrating D-peptide DPMI-g-DR9 rapidly induced
p53-independent cytotoxicity (Liu et al., 2010). The positively
charged CPPs from N-terminal prion proteins also elicited mem-
brane leakage in defined large unilamellar phospholipid vesicles
(Magzoub et al., 2005). It is also worth noting that the unstapled
DPMI-g-DR9 (Liu et al., 2010), TAT-PMI, and PMI-s-s-TAT pep-
tides induce severe membrane damage (Figure 7) and cytotox-
icity, indicating that chemical stapling per se is not required for
cytotoxicity (Okamoto et al., 2014).
The ReBiL strategy provides a facile platform system for PPI
analyses. We have shown that this system can detect interac-
tions between UBE2T-FANCL (Figure 2), p53-Mdm2, p53-
Mdm4 (Figure 3), Mdm2-Mdm4 RING domains (Figure S6), and
BRCA1-BARD1 RING domains (Figures 5C and S7), among
other proteins (Y.-C.L. and G.M.W., unpublished data). Further-
more, the very high signal-to-noise ratio in the lysate format
enabled ReBiL to be used for high-throughput drug screens in
a 1,536-well format with Z0 values exceeding 0.7 (Y.-C.L.,
G.M.W., and K.F.W., unpublished data). We expect ReBiL to
have broad applications ranging from identifying noncoding
RNAs that facilitate cytosolic PPIs to assessing factors that
impact plasma membrane-associated KRAS dimerization,
neither of which is feasible using other strategies, such as
the two-/three-hybrid systems with transcriptional readouts.
Together, these attributes should enable ReBiL to broaden ourports 9, 1946–1958, December 11, 2014 ª2014 The Authors 1955
understanding of the impact of disease-relevant mutations on
protein interactions, elucidate the mechanisms of drug action
more precisely, improve the efficacy of PPI antagonists, and
advance our understanding of the makeup of the human protein
interactome.
EXPERIMENTAL PROCEDURES
Construction of ReBiL Targeting Plasmids
We used standard molecular biology methods and the Gibson Assembly strat-
egy (E2611S; New England Biolabs) to construct all of the ReBiL targeting
plasmids. See Table S2 for details.
Real-Time BiLC Assay in Living Cells
Phenol-red free Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Life Tech-
nologies or Sigma-Aldrich) containing 23 concentrated reagents, including
doxycycline (Sigma-Aldrich) and D-luciferin (potassium salt, L-8220; Bio-
synth), were pipetted into a 384-well plate (Corning) at 20 ml per well. The cells
were trypsinized and cell numbers were determined. The required number of
cells were collected into 1.5 ml LoBind tubes (Eppendorf) and spun at
200 rcf for 5 min at room temperature. The cells were resuspended with
DMEM/F12 (phenol-red free) and 20 ml of cells were pipetted into each well.
The final concentration of each component was as follows: FBS 10%, cipro-
floxacin 10 mg/ml, doxycycline 0–500 ng/ml, and D-luciferin 100–200 mM
(5,000–20,000 cells per well). The plate was sealed with MicroAmp Optical
Adhesive Film (Life Technologies) and luminescence was read in a Tecan
M200 microplate reader (integration time 2 s, 10–30 min per cycle for a total
of 24–48 hr at the indicated temperature).
DoxycyclineWithdrawal Strategy to Enable Real-Time BiLCAnalysis
of Protein Complex Dissociation
To evaluate small-molecule PPI antagonists, the ReBiL cells were first cultured
in 10- to 15-cm dishes with regular media containing doxycycline (500 ng/ml)
and D-luciferin (100 mM) for 24 hr. The next day, the cells were trypsinized and
cell numbers were determined. Cells were seeded into assay plates as
described above except that doxycycline was eliminated from the media. To
evaluate SAH peptides, the cells were seeded into a 96-well plate (Corning)
at 20,000 cells per well and incubated in the presence of doxycycline
(500 ng/ml) and D-luciferin (100 mM) for 24 hr. The next day, the media were
aspirated, cells were washed once with DMEM, and 50 ml of DMEM/F12
(phenol-red free) media containing D-luciferin (100 mM) and the stapled pep-
tides at the indicated concentrations was added into each well. The plate
was sealed with MicroAmp Optical Adhesive Film and luminescence was
read in a Tecan M200 microplate reader (integration time 2 s, 5–10 min per
cycle for a total of 6 hr at 37C).
Cell Viability Assay
Luminescence-based cell viability assays were performed using CellTiter Glo
(Promega), which measures the amount of ATP produced by viable cells,
according to the manufacturer’s protocol. Luminescence was detected in a
Tecan M200 microplate reader with an integration time of 0.5 s. Trypsinized
cells were treated with Trypsin inhibitor (Sigma-Aldrich) and then seeded
into serum-free media for viability assays.
BiLC Assay using Cell Lysates
Saos-2 or U2OS ReBiL cells were cultured in regular media with doxycycline
(500 ng/ml, 48–72 hr). The 43 concentrated drugs diluted in DMEM/F12media
were pipetted into 384-well plates at 10ml per well. Cells with loadedBiLC com-
plexes were washed and lysed with PLB buffer (100 mM Tris-HCl [pH 7.5],
0.5mMEDTA, 150mMNaCl, 0.1%Triton X-100, 1mMsodium orthovanadate,
50mMsodium fluoride, and Roche CompleteMini Protease Inhibitor Cocktail).
The cell lysateswere transferred into 1.5ml tubes and cleared by centrifugation
(13,000 rcf, 5 min at 4C). The clear lysates were collected and diluted with
DMEM (300 ml DMEM added into 100 ml lysates). Then 10 ml of diluted lysates
was immediately pipetted into each of the 384-well plates containing drugs,
and the plates were incubated at room temperature for 10 min. Finally, 20 ml1956 Cell Reports 9, 1946–1958, December 11, 2014 ª2014 The Autof luciferin reagents (Bright-Glo E2620 or Steady-Glo E2520, Promega) was
added into each well and luminescence was read in a Tecan M200 microplate
reader (integration time 0.5 s, 3–5 min per cycle for 30 min at 26C).
LDH Leakage Assay
LDH leakage was detected with the CytoTox 96 Non-Radioactive Cytotoxicity
Assay Kit (Promega) per the manufacturer’s protocol. For details, see the Sup-
plemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.10.058.
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